Angle PLC 2021 AR2
The report highlights ANGLE plc's progress in 2021, including the establishment of clinical laboratories in the UK and US under the 'Onc-ADaPT Labs' brand and the launch of its global pharma services business. The company completed patient enrolment for its ovarian cancer clinical verification study and continued its De Novo FDA submission process for the Parsortix system in metastatic breast cancer. Additionally, the company partnered with World Wide Generation to implement the G17Eco platform for tracking its ESG metrics. Financially, the company raised #20.0 million in a June 2021 fundraise to support its commercialisation activities.
Company: Angle PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2021
Type: AR2
Pages: 130
Back to company
Angle PLC
Annual Report And Financial Statements
The report highlights ANGLE plc's progress in 2021, including the establishment of clinical laboratories in the UK and US under the 'Onc-ADaPT Labs' brand and the launch of its global pharma services business. The company completed patient enrolment for its ovarian cancer clinical verification study and continued its De Novo FDA submission process for the Parsortix system in metastatic breast cancer. Additionally, the company partnered with World Wide Generation to implement the G17Eco platform for tracking its ESG metrics. Financially, the company raised #20.0 million in a June 2021 fundraise to support its commercialisation activities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees